U.S Court of Appeals Upholds Myriad's Gene Patents
"We are very pleased with the favorable decision the Court rendered today which again confirmed that isolated DNA is patentable," said
It is important to correct some common misconceptions on the societal impact of "gene" patents; namely that such patents impede research, result in high-cost testing and takeaway a patient's option for second-opinion testing. Myriad believes that statements made to these points in the public press are incorrect. To set the record straight,
- "Gene" patents have not hindered research on BRCA 1 and BRCA 2 and Myriad has never denied, opposed or impeded any research studies on these, or any other, genes. Further, more than 18,000 scientists have researched the BRCA genes, publishing more than 9,000 research papers.
The cost of the BRACAnalysis test is not prohibitive and patient access is extensive. Myriad has provided close to one million patients with BRACAnalysis test results. Approximately 95% of appropriate patients in
the United Stateshave access to BRACAnalysis either through private insurance, Medicare, Medicaidor Myriad's Financial Assistance Program, which provides coverage at no charge to low-income, uninsured patients. Over the past 3 years alone, more than 5,000 patients have benefitted from this assistance program.
- Lastly, second opinion testing is available for patients with positive test results in a number of U.S. laboratories, including a large reference laboratory licensed by Myriad in 2001.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scope and strength of the Company's patents and the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to develop or achieve commercial success
for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside
Rebecca ChambersDirector, Investor Relations and Corporate Communications (801) 584-1143 firstname.lastname@example.org
News Provided by Acquire Media